Back to Search Start Over

Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy.

Authors :
Liu, Wei
Huang, Wenyang
Wang, Min
Lv, Rui
Li, Jian
Wang, Ying
Deng, Shuhui
Yi, Shuhua
Liu, Hong
Rao, Qing
Xu, Yingxi
Lv, Lulu
Qiu, Lugui
Zou, Dehui
Wang, Jianxiang
Source :
British Journal of Haematology; Oct2020, Vol. 191 Issue 1, p126-129, 4p
Publication Year :
2020

Details

Language :
English
ISSN :
00071048
Volume :
191
Issue :
1
Database :
Complementary Index
Journal :
British Journal of Haematology
Publication Type :
Academic Journal
Accession number :
146138504
Full Text :
https://doi.org/10.1111/bjh.16951